Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SPGJY
ADC Name
Cetux Cys-vc-MMAE
Synonyms
Cetux Cys vc MMAE
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Glioblastoma [ICD11:2A00]
Investigative
Drug-to-Antibody Ratio
3.2
Antibody Name
Glyco-engineered cetuximab
  Antibody Info 
Antigen Name
Epidermal growth factor receptor (EGFR)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Specific conjugation via Cys to the antibody using a bacterial sialyltransferase (AST-03)
Combination Type
Vedotin
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.03
nM
U-87MG cells
Glioblastoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.03 nM High EGFR expression (EGFR+++)
Method Description
The effect of MMAE-conjugated cetuximab ADCs on the viability of U87 glioblastoma cells that express EGFR.
In Vitro Model Glioblastoma U-87MG cells CVCL_0022
References
Ref 1 MAbs. 2023 Jan-Dec;15(1):2149057. doi: 10.1080/19420862.2022.2149057.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.